Attovia Therapeutics, Inc.

Attovia Therapeutics, Inc. , based in the US, specializes in developing precision biologics that address immune-mediated diseases, leveraging its ATTOBODY™ platform for innovative multispecific therapies. Founded in 2023 and headquartered in San Carlos, California, Attovia Therapeutics, Inc. focuses on advancing treatments for immune-mediated diseases.

The company has conducted 4 deals to date, with its latest funding round being a Series C that raised USD 90. 00 mn on April 15, 2025, led by Deep Track Capital with participation from notable investors such as Frazier Healthcare Partners and Goldman Sachs. The total amount raised by the company is USD 90. 00 mn, and its current valuation stands at USD 335.

27 mn. Attovia's core product offerings center around a new generation of precision biologics that address high unmet needs across immune-mediated diseases. The company utilizes its proprietary ATTOBODY™ platform, a modular protein design technology that enables the creation of multispecific medicines capable of targeting multiple disease pathways simultaneously. This innovative approach aims to improve therapeutic performance and provides solutions for patients who remain undertreated by existing single-pathway treatments.

Attovia's products are positioned to benefit a diverse client base that includes healthcare providers, patients, and pharmaceutical partners, particularly in North America, Europe, and Asia, where there is a significant demand for advanced therapeutic options in the immunology landscape. The focus of Attovia's development efforts is to enhance patient outcomes and expectations regarding treatment efficacy and safety. Attovia generates revenue through strategic partnerships, collaborations, and potential licensing agreements related to its multispecific biologics. The company's revenue model includes B2B transactions, where it engages with pharmaceutical firms interested in co-developing or licensing its innovative therapies.

The structure of these transactions may involve milestone payments and royalties based on product sales, reflecting the value of Attovia’s proprietary technologies and their application in clinical settings. While specific pricing plans for individual products are not disclosed, the revenue framework is designed to capitalize on the successful integration of its ATTOBODY™ platform within broader therapeutic portfolios of its partners, creating a sustainable financial ecosystem as its products progress through development and into the market. Attovia Therapeutics plans to utilize the recently raised USD 90. 00 mn from its Series C funding round to further develop its ATTOBODY-based therapies and expand its pipeline of multispecific treatments targeting immune-mediated diseases.

The company aims to launch new products within the next few years and is actively exploring expansion into key markets in North America, Europe, and Asia by 2026. The funding will significantly support these initiatives, allowing Attovia to pursue its ambitious growth strategy while addressing the needs of patients with complex immune-related conditions.